NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Yarrow Bioscience Inc (YARW) Stock Analysis

Yarrow Bioscience Inc (YARW) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

YARW

$30.21

+$1.36 (+4.71%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare YARW with… →

YARW Key Statistics

As of Sep 4, 2026
Trading
Open
$29.34
Previous Close
$28.85
Day's Range
29.04–31.90
52-Week Range
14.05–46.95
Volume
26.60K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
2.07
Valuation
Market Cap
$80.65M
Financials (FY)
Profit marginThe share of revenue left as profit after all costs and taxes.
0.00%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
2.67M
1-Year Return
+244.18%
Dividend and dates
Ex-Dividend Date
July 24, 2026
Avg Volume
29.28K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

YARW Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+84.55%
2025−82.69%
2024+43.78%
2023−13.70%
2022−85.29%
2021−83.86%
2020−65.95%
2019+12.62%
2018−85.65%

As of September 4, 2026.

YARW Valuation vs Biotechnology Median

Median of 656 stocks
MetricYARWBiotechnology medianvs median
Profit margin0.00%0.00%0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

Yarrow Bioscience Inc (YARW) carries a market capitalisation of $80.65M. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 7 employees.

The most recent close on file for YARW is $30.21, dated September 4, 2026. That is +$1.36 (+4.71%) against the previous close. Over the past 52 weeks the price has ranged from $14.05 to $46.95. The latest close sits 115.02% above that 52-week low.

Financial Health

The reported profit margin is 0%.

Valuation Assessment

Beta against the wider market is reported at 2.07. Annualized volatility over the trailing 8 years is 101.44%. Over the trailing twelve months the price has returned +244.18%. Across 5 years the annualized return works out at −48.68%.

Growth & Income

No dividend is on file for YARW.

The strongest complete calendar year on file is 2024 at +43.78%; the weakest is 2018 at −85.65%. Of the 8 complete calendar years on file, 2 finished higher. So far in 2026 the price is +84.55%.

Peer Comparison

Yarrow Bioscience Inc (YARW) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Yarrow Bioscience Inc YARW $80.65M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Yarrow Bioscience Inc has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Yarrow Bioscience Inc

Yarrow Bioscience, Inc. operates as a clinical-stage biotechnology company that engages in developing transformative therapies for autoimmune thyroid diseases. The company's candidate, YB-101, is a humanized monoclonal antibody targeting the thyroid-stimulating hormone receptor (TSHR) for the treatment of Graves' disease and thyroid eye disease. The company was incorporated in 2025 and is based in New York, New York.

Visit website →